The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists

McAlister FA Wilkins K Joffres M . Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 2011;183:1007-13.

Houle SKD Tsuyuki RT Campbell NRC . The Canadian Hypertension Education Program (CHEP) 2011 guidelines for pharmacists. Can Pharm J (Ott) 2011;144:295-304.

McKay DW Godwin M Chockalingam A . Practical advice for home blood pressure measurement. Can J Cardiol 2007;23:577-80.

Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. Eur Heart J 2007;28:1462-536.

Pickering TG Davidson K Gerin W Schwartz JE . Masked hypertension. Hypertension 2002;40:795-6.

Liu JE Roman MJ Pini R . Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med 1999;131:564-72.

Ohkubo T Kikuya M Metoki H . Prognosis of “masked” hypertension and “white coat” hypertension detected by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 2005;46:508-15.

Daskalopoulou SS Khan NA Quinn RR . The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk and therapy. Can J Cardiol 2012;28:270-87.

Houle SKD Campbell NRC Tsuyuki RT . Home blood pressure monitoring plays a key role in hypertension management: review of applications, effectiveness and technique for pharmacists. Can Pharm J (Ott) 2011;144:18-20.

Upadhyay A Earley A Haynes SM Uhlig K . Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011;154:541-8.

Klahr S Levey AS Beck GJ . The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84.

Wright JT Jr Bakris G Greene T . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31.

Ruggenenti P Perna A Loriga G . Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365:939-46.

The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-7.

Pitt B Remme W Zannad F . Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.

Zannad F McMurray JJV Krum H . Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.

Beckett NS Peters R Fletcher AE ., for the HYVET study group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98.

Gueyffier F Bulpitt C Boissel JP . Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999;353:793-6.

Lim SS Vos T Flaxman AD . A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224-60.

Mathers C Stevens G Mascarenhas M . Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009. Available: www.who.int/healthinfo/global_burden_disease/global_health_risks/en/index.html (accessed Feb. 12, 2012).

Hypertension Canada. Healthy blood pressure in Canada: a discussion paper on the way forward. Available: www.hypertension.ca/images/stories/dls/framework/Final_FrameworkRevised_EN_(Sept_2011).pdf (accessed April 2, 2013).